Reverse DCF
What growth does the market imply for JUBLPHARMA?
Working backwards from the current price to find the FCF growth assumption baked in.
conservative
7.8% implied annual FCF growth
The market is pricing in below-GDP growth — very conservative assumption. If the company delivers anywhere near its historical rate, there is significant upside.
Current Price
₹977
Historical Growth
0.2%
FCF Yield
4.59%
Price / FCF
21.8x
Plain English
To justify today's price of ₹976.75, JUBLPHARMA.NS needs to grow its free cash flow at 7.8% per year for the next 10 years. That is 7.6% faster than its historical growth rate of 0.2%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 0.2% | ₹491 | -49.7% |
| Half implied | 3.9% | ₹692 | -29.2% |
| Implied | 7.8% | ₹977 | +0.0% |
| GDP rate | 10.0% | ₹1,189 | +21.7% |
At Historical Growth Rate
DCF horizon: 10 years. At 0.2% growth, the model values JUBLPHARMA at ₹491, below today's ₹977.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.